Niet gecategoriseerd

01 April 2025 On April 11, Stephanie Anbuhl and Gillian Dekkers will be present at the Fletcher Hotel Sparrenhorst in Nunspeet to join scientists for the 5th Dutch Complement Symposium. Visit our stand to have a chat and discuss single-domain antibodies to target the complement system and more.

02 April 2025 We’re celebrating 15 years! To mark this special milestone, we’re offering a 15% discount on all productions requested throughout the month of April! This offer is valid for all production requests made in April. Don’t miss out on this opportunity—contact us today and let’s create something amazing together!

20 March 2025 This month marks a special milestone in QVQ’s history: our 15th anniversary! Since our founding in 2010, we have been dedicated to advancing the field of biotechnology with a focus on single-domain antibodies. Thanks to the dedication, and hard work of our growing team, we have built a reputation as a trusted partner for single-domain antibody services, collaborating with our customers on innovative discovery, characterization, and engineering projects that push boundaries. As we reflect on these 15 years, we are more excited than ever about the future. We are committed to continuing our growth journey, embracing new technologies such as synthetic biology, structural biology, and machine learning to continue to deliver high-quality single-domain antibodies using fewer animals. … Read more

25 March 2025 QVQ is proud to be the platinum sponsor of THE conference dedicated to the smallest antibody fragment class. We would like to welcome you to mingle with sdAb experts from industry and academia in the fantastic city of Utrecht in September to brainstorm on how single-domain antibodies can further increase their impact on society.

12 March 2025 This paper, published this week in Bioconjugate Chemistry, is the result of a fruitful collaboration of Stephanie Mareike Anbuhl, Matti Pronker, and Raimond Heukers from QVQ Holding BV and from the group of Prof. Frederik Cleeren at KU Leuven. The sdAb VUN400c proves to be a valuable tool for imaging CXCR4-expressing tumors in vivo. Indium-labeled VUN400c demonstrates tumor-specific uptake and shows promising results in SPECT imaging.Congratulations to all co-authors! QVQ offers this sdAb (Q84) with or without cysteines for conjugations to chelators and many other labels.

05 March 2025 Next week, Stephanie Mareike Anbuhl will be in Bilbao to join scientists from around the world to discuss the latest developments in molecular imaging. Stephanie will present her poster “Functionalized single-domain antibodies for detecting and imaging GPCR complexes on cancer cells” (Poster# ONCO-006, first session). She will be available for scientific discussions on conjugation of VHHs and the value of these molecules in imaging applications. Will we see you there?

11 February 2025 Today we celebrate the International Day of Women and Girls in Science! This day is a reminder to acknowledge and honour the incredible contributions of women and girls in science, technology, engineering, and mathematics (STEM). While significant progress has been made towards gender equality in these fields, a report of the United Nations shows that there is still work to be done. At QVQ, we are proud to have a diverse team. We believe that diversity strengthens our team and supports innovation and excellence in everything we do. QVQ’s growing success is a testament to the power of an inclusive environment where everyone has the opportunity to thrive. We will continue to support and encourage women and … Read more

04 February 2025 Today is World Cancer Day — a day where millions of people worldwide come together to raise awareness about the importance of education, care, and research in the fight against cancer. Cancer is not just one disease, but a complex group of many, making each case unique and the journey of diagnosis and therapy as well as cancer research highly challenging. Thanks to the ongoing efforts of academia and industry, there is continuous progress with constantly improving treatment options. Yet, the fight against cancer is far from over. While QVQ has no drug pipeline of its own, we do take pride in making a meaningful impact by offering services and products that empower our collaborators and customers … Read more

22 January 2025 End of January, Raimond Heukers and Stephanie Mareike Anbuhl will be present at the Bimhuis in Amsterdam to join scientists from the Vrije Universiteit Amsterdam (VU Amsterdam) and other companies for the 2025 AIMMS festival organized by AIMMS VU. Visit our stand to chat with us and discuss the generation and various applications of single-domain antibodies.

15 January 2025 Mark your calendars and join us in 2025: ➡️ HollandBio Year Event – 25 January 2025 – De Flint, Amersfoort, The Netherlands ➡️ European Molecular Imaging Meeting l EMIM – 11-14 March 2025 – Bilbao, Spain ➡️ Antibody engineering and Therapeutics – 10-12 June 2025 – Basel, Switzerland ➡️ 4th Single-Domain Antibodies Conference – 29 September – 1 October 2025 – Jaarbeurs, Utrecht, The Netherlands For more information, contact us at info@qvquality.com. We look forward to seeing you there!

14 January 2025 In this recent preprint, researchers from the VU, AUMC, and QVQ, use single-domain antibodies (sdAbs) to modulate the chemokine receptor CXCR4. Mobach and Bergkamp et al utilize the sdAb VUN401, which disrupts clusters of CXCR4 on lymphoma cells. This monomerization of CXCR4 impairs cancer cell growth and migration and sensitizes cancer cells for apoptosis. CXCR4-targeting sdAbs are available at QVQ as labeled and unlabeled proteins.

08 January 2025 QVQ offers unique single-domain antibodies against the class A G protein-coupled receptor CXCR4 (e.g. Q84 and Q85).In this study, QVQ, together with the group of Professor Martine Smit, further improved the already high affinity and antagonistic potency of one of these sdAbs by constructing various multivalent formats. Among all generated formats with up to ten VHH domains in one construct, VHH-Fc stood out as particularly effective for improving affinity and potency. The CXCR4-targeting sdAbs Q84 and Q85 are available as non-modified, cysteine-tagged, and conjugated or genetically fused protein.